Cite
HARVARD Citation
Vatish, J. et al. (2019). P089. Neoadjuvant Pertuzumab in the treatment of HER2+ve breast cancer: Increased Pathological Complete Response, but at a cost?. European journal of surgical oncology. 45 (5), pp. 908-909. [Online].